The 2 most recent market catalysts affecting $DCOY, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 29, 2026
Corporate Catalyst
Bullish
Impact 65
Decoy Therapeutics Says Preclinical Data Show Single Intranasal Dose Of DCOY-CoV Maintains Drug Levels For Up To 7 Days; Expects Clinical Trials In 2027
This headline is a positive corporate catalyst for Decoy Therapeutics. The preclinical data indicating sustained drug levels for up to 7 days with a single intranasal dose is a sig…
Sep 22, 2026
Corporate Catalyst
Bullish
Impact 55
Decoy Therapeutics Announces Its Exploring Non-Dilutive Federal Grants, Public Health Collaborations To Support Preclinical, Clinical Development Of Biodefense Pipeline
Decoy Therapeutics is shifting its corporate strategy to focus on biodefense, specifically a pan-filovirus program, and is seeking non-dilutive federal grants and public health col…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.